161 related articles for article (PubMed ID: 30447756)
1. Neurofibromatosis type 1 as a model system to study molecular mechanisms of autism spectrum disorder symptoms.
Molosh AI; Shekhar A
Prog Brain Res; 2018; 241():37-62. PubMed ID: 30447756
[TBL] [Abstract][Full Text] [Related]
2. Characterization of early communicative behavior in mouse models of neurofibromatosis type 1.
Maloney SE; Chandler KC; Anastasaki C; Rieger MA; Gutmann DH; Dougherty JD
Autism Res; 2018 Jan; 11(1):44-58. PubMed ID: 28842941
[TBL] [Abstract][Full Text] [Related]
3. Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.
Haebich KM; Pride NA; Walsh KS; Chisholm A; Rouel M; Maier A; Anderson V; Barton B; Silk T; Korgaonkar M; Seal M; Lami F; Lorenzo J; Williams K; Dabscheck G; Rae CD; Kean M; North KN; Payne JM
BMJ Open; 2019 Sep; 9(9):e030601. PubMed ID: 31558455
[TBL] [Abstract][Full Text] [Related]
4. Modeling cognitive dysfunction in neurofibromatosis-1.
Diggs-Andrews KA; Gutmann DH
Trends Neurosci; 2013 Apr; 36(4):237-47. PubMed ID: 23312374
[TBL] [Abstract][Full Text] [Related]
5. Neurofibromatosis Type 1 Implicates Ras Pathways in the Genetic Architecture of Neurodevelopmental Disorders.
Kaczorowski JA; Smith TF; Shrewsbury AM; Thomas LR; Knopik VS; Acosta MT
Behav Genet; 2020 Jul; 50(4):191-202. PubMed ID: 32026187
[TBL] [Abstract][Full Text] [Related]
6. Neurobehavioral sex-related differences in Nf1
Santos S; Martins B; Sereno J; Martins J; Castelo-Branco M; Gonçalves J
Biol Sex Differ; 2023 Apr; 14(1):24. PubMed ID: 37101298
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of pharmacological inhibition of anaplastic lymphoma kinase in neurofibromatosis 1 mutant mice.
Krenik D; Weiss JB; Raber J
Behav Brain Res; 2022 Apr; 423():113767. PubMed ID: 35077772
[TBL] [Abstract][Full Text] [Related]
8. Disruption of Critical Period Plasticity in a Mouse Model of Neurofibromatosis Type 1.
van Lier M; Saiepour MH; Kole K; Cheyne JE; Zabouri N; Blok T; Qin Y; Ruimschotel E; Heimel JA; Lohmann C; Levelt CN
J Neurosci; 2020 Jul; 40(28):5495-5509. PubMed ID: 32527982
[TBL] [Abstract][Full Text] [Related]
9. An executive functioning perspective in neurofibromatosis type 1: from ADHD and autism spectrum disorder to research domains.
Smith TF; Kaczorowski JA; Acosta MT
Childs Nerv Syst; 2020 Oct; 36(10):2321-2332. PubMed ID: 32617712
[TBL] [Abstract][Full Text] [Related]
10. Molecular and cellular mechanisms of learning disabilities: a focus on NF1.
Shilyansky C; Lee YS; Silva AJ
Annu Rev Neurosci; 2010; 33():221-43. PubMed ID: 20345245
[TBL] [Abstract][Full Text] [Related]
11. A Targeted, Low-Throughput Compound Screen in a
Dyson A; Ryan M; Garg S; Evans DG; Baines RA
eNeuro; 2023 May; 10(5):. PubMed ID: 37185294
[TBL] [Abstract][Full Text] [Related]
12. Loss of
Dyson A; Ryan M; Garg S; Evans DG; Baines RA
J Neurosci; 2022 Dec; 42(50):9450-9472. PubMed ID: 36344265
[TBL] [Abstract][Full Text] [Related]
13. Human stem cell modeling in neurofibromatosis type 1 (NF1).
Wegscheid ML; Anastasaki C; Gutmann DH
Exp Neurol; 2018 Jan; 299(Pt B):270-280. PubMed ID: 28392281
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibition of Anaplastic Lymphoma Kinase rescues spatial memory impairments in Neurofibromatosis 1 mutant mice.
Weiss JB; Weber S; Marzulla T; Raber J
Behav Brain Res; 2017 Aug; 332():337-342. PubMed ID: 28629962
[TBL] [Abstract][Full Text] [Related]
15. Neurofibromatosis type 1.
Cimino PJ; Gutmann DH
Handb Clin Neurol; 2018; 148():799-811. PubMed ID: 29478615
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous and Engineered Large Animal Models of Neurofibromatosis Type 1.
Osum SH; Watson AL; Largaespada DA
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669386
[TBL] [Abstract][Full Text] [Related]
17. Dissecting Clinical Heterogeneity in Neurofibromatosis Type 1.
Monroe CL; Dahiya S; Gutmann DH
Annu Rev Pathol; 2017 Jan; 12():53-74. PubMed ID: 28135565
[TBL] [Abstract][Full Text] [Related]
18. Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial.
van der Vaart T; Plasschaert E; Rietman AB; Renard M; Oostenbrink R; Vogels A; de Wit MC; Descheemaeker MJ; Vergouwe Y; Catsman-Berrevoets CE; Legius E; Elgersma Y; Moll HA
Lancet Neurol; 2013 Nov; 12(11):1076-83. PubMed ID: 24090588
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of Ion Channels Contributes to Central and Peripheral Dysfunction in Neurofibromatosis Type 1.
Moutal A; Dustrude ET; Khanna R
Mol Neurobiol; 2017 Jul; 54(5):3342-3349. PubMed ID: 27167129
[TBL] [Abstract][Full Text] [Related]
20. ERK/MAPK signaling and autism spectrum disorders.
Vithayathil J; Pucilowska J; Landreth GE
Prog Brain Res; 2018; 241():63-112. PubMed ID: 30447757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
